Jefferies Global Healthcare Conference in London - 4D MOLECULAR THERAPEUTICS INC
All right. Good afternoon, everyone. Thank you for joining us today. My name is Faisal Khurshid, Senior Biotech Analyst at Jefferies. Really pleased to have with us today live in London at the Jefferies Global Healthcare Conference, the management team of FDMT, 4D Microtherapies. Just to kick us off, David's going to start with a few slides, and then we'll go into Q&A after that. So, David, let me pass to you. Fantastic. Thanks for having us. All right. We're going to dive right in here. Typical legal disclaimer. Okay. So today we're going to be focused on our lead asset 4150, which we think has the potential to create a new treatment paradigm in wet AMD and other neovascular diseases. I've got four key takeaways for you today. Number one is with a single intravitreal injection routine out clinic injection into the vitreous. We believe this will result in a continuous backbone treatment for patients throughout the rest of their life. So that means this disease that's waxing and waning but always on will be treated with a disease treatment that's always on. Number two, we think that 4150 has the potential to address the two highest summit needs in wet AMD, and that is treatment burden. It's very, very high. We want to bring that down and also maintain vision over time. Number three, we believe our phase two clinical results and our phase three design has really set us up for success together with our excellent execution in terms of enrollment. And finally, number four, from Chris today, we believed 4150 has huge commercial potential based on our interactions and interviews with payers, physicians, and patients. Okay. So to remind you, 4150 has a proprietary capsid that we invented through a Nobel Prize winning technology called directed evolution. This allows us to use an intravitreal injection instead of subretinal at a very low dose and low inflammatory risk and still transduce the retina broadly. Our payload is a Flibercept plus a VEGFC RAI. So we have the potential to treat, hit four different molecular targets here. And again, the primary mechanism of action here is the Aflibicept, which has been in over 60 million eyes safely and effectively. So we're expressing a very well-validated biologic and market leader. So on the top, what you can see is a representation of the disease activity in wet AMD. So these patients have this disease for the rest of their life after diagnosis. It waxes and wanes in terms of intensity, but it's always there. Unfortunately, the current bolus anti-VEGFs, huge market, but still undertreat the disease. And what you can see is on the bottom row there, the typical treat and extend concentrations of anti-VEGF bolus therapies in the vitreous, where you get a high spike, and then it's gone. And over time, physicians try to extend patients to decrease the treatment burden, which means for large periods of time the patient is untreated with this severe chronic disease. So we believe with a continuous backbone treatment with a gene therapy expressed from the retina, we have the potential to continuously protect patients from disease activity for the rest of their life, which is a real game changer. Why is this important? Well, beyond just reducing treatment burden, which will have a huge impact on quality of life, there's also the potential to maintain vision. So to remind you, as you can see in the dashed line, with real-world data on bolus anti-VEGF therapeutics, patients lose vision. So despite these being potent biologics, they lose vision, we believe with a continuous backbone therapy, we can maintain vision for the rest of the patient's life. This is data from our two-year results from a recently diagnosed population, so as close as we have to Phase III population, And you can see over two years, a nice control of the central subfield thickness on the top and also maintenance of best corrected visual acuity over two ears, which is very important. And then also important on the right is you see a treatment burden reduction estimate for these patients being close to 90% treatment burden reductions. So that's a real game changer for these patient. And roughly two-thirds were still free of the need for any supplemental bolus injections at two years. Safety is critical in a large disease like this. We are pioneers in terms of bringing gene therapy to a large market. And you can see here in green, this shows you the percentage of patients at each time point who are free of inflammation. You can see from six months on, 100% are freeof inflammation. During the first six months, we have a couple of patients who had mild inflammation, which was easily controlled with topical steroid eye drops. And importantly, no significant serious adverse events or vision-threatening complications were described. So to reiterate, 4150 is really designed to be a potential backbone therapy for continuous disease control. And again, we believe this will be lifelong, will preserve vision, reduce treatment burden. And again, we believe the safety profile today has been very predictable and favorable, and this is all achieved with a single intravitreal injection in the clinic. Briefly, our Forefront 1 and Forefront 2 Phase 3 trials are both North America and global, both very well-powered with roughly 520 to 530 patients on each, and we have strong regulatory alignment globally. The patient population here has been optimized based on what we saw in phase two. So we exclude patients with extreme CST. Those outliers are excluded. And then we also require a response to a flibber step on study to make sure these are highly responsive patients. The other issue that's very important in these sort of non-inferiority studies for BCVA is what are the supplemental injection criterias that patients can receive to protect their BCVA. And here we've got a broad range of criteria that will help to protect the BCVA patients. If they get more too severe progression on CST, they'll be rescued. On vision alone, they will be rescued, and then also with the combination of five letters and 50 microns, they ll also be rescued so we think these are strong criteria that would protect the primary endpoint of BCVA in this study, and still give us a large treatment burden reduction. So 26 has been a busy year for us. You can see in the checks broad progress across WET-AMD, DME, and at the company level. Our main upcoming readouts are Q2 2027 will be the forefront one phase three and the second half of 27 for the forefront two readouts. So very important upcoming data releases coming, and we're in a strong cash position. So those are our introductory comments. Thank you. Awesome. Thank you, David. So we can get into some Q&A now. Yeah, feel free to join me here. So one thing I want to just understand is that within wet AMD, I think you laid out nicely that there's sort of this perpetual need for treatment and what you're essentially measuring in the disease in addition to anatomy me is like how burdensome is the treatment which i mean if you kind of take a step back it's kind of a wild concept i mean your goal is to really create a step change in that but could you like help quantify for us like i was like the data that you just ran us through it's amazing it's paradigm shifting but what you know what level do you need to see in phase three to kind of continue to bolster that right because the bar set by your phase two data is like it's sky high Where do you need to land to feel good about your phase three? Sure. Why don't we start with Chris Sims, our chief commercial officer. He can weigh in on kind of what we've seen with prior products and what we expect to see here. Yeah, happy to. Thanks for the opportunity to be here. So maybe a quick kind of walk down history lane really quick. Anti-veg F's has been injected in the eye for 20 years, right, since the introduction of Lucentis. Large markets, $16 billion approximately globally. Markets continue to grow every year. And there's been innovation. What's been interesting is that every new agent that's come to market, everything has been in the pursuit of durability. And when you think of it from a patient's perspective, needles in your eye every 4, 6, 8, 12 weeks, if you can reduce that, obviously that's of immense value. But everything that's comes to market – if you look at the advisement on LEHD compared to what standard of care was, the incremental benefit as measured by a percentage of treatment burden reductions is about 20%, right? And we looked at real-world data recently. We went back to 2021 for a five-year look back, and that's in the period where longer-acting agents like Vibizumab have come to market, and the average real-World increase in durability has been about 10 days. So there's been a delta, for sure, but largely incremental. And despite that incremental benefit, these medicines have become multi-blockbusters. If it buys them, I think lately it's on track to be a $4 to $5 billion drug for Roche with the benefit of about two weeks of incremental durability. So I share that history lesson just to give you context as to what will be meaningful here. Well, meaningful in the past with these bolus therapies has been, you know, about 20%. We're seeing results through our Phase II program in the 80%, 90% range by comparison. And so we think we're well-positioned to, as you mentioned, be a paradigm-shifting therapy in terms of reduction of treatment burden. But the benefit, as David went through, goes beyond just the durability impact. All of these newer therapies that, again, have produced incremental benefits in durability, what we know in the real world is that despite the innovation that's come with these therapies, patients still lose vision because they're bolus in nature, and patients generally are still undertreated, thus connecting back to the fact that they lose vision. So a backbone therapy that provides continuous disease control not only has the potential to massively reduce the burden of treatment, but it also has the possibility of allowing a patient to hold on to that vision where all these bolus therapies, I think, are handicapped in their ability to do that. Got it. Makes sense. And then I want to also discuss a little bit about the competitive landscape, because obviously we're waiting for your forefront trials to read out next year. I think you guys did some really smart kind of things on the trial design that I want to get into as well. But before we get that, we're going to see at least a couple of competitive readouts. So for a lot of investors, they're trying to think through, like, how do we sort of invest here? How do we deal with this kind of catalyst path that's ahead of you? How would you guide investors on how to think about going through the Cirovec and Exavec data on the way to the forefront data? Sure. So first of all, you point out it's an exciting time for gene therapy in wet AMD and ultimately DME. So I think we see this critical groundswell of realizing this is the future for this area. It's not longer-acting bolus therapies. Gene therapy is the feature, and it's coming fast. So the Cerovec subretinal injection product with AbbVie and Regenexx, certainly is positioned for success. You know, their patient population is a little bit different. They produce Lucentis, whereas we produce the equivalent of Aflibricept, which we believe is more potent, and we have a VEGFC component that they don't. So there are differences like that, and certainly we think intravitreal is a much, much better way to deliver to cover the whole retina and also from a commercialization standpoint. point. But that having been said, you know, we certainly hope that they're successful. There may be surgery-related complications that we won't see. But, you know, I think there are certainly differences, but also some similarities. And we wish them the best and hope they succeed. And then the Ixovec, following that, you know we'll just have to see. I think that's one that's been handicapped by the history of toxicity, severe toxicity in the DME that they're now trying to overcome, and, you know, we'll see if they can achieve an effective safety profile in wet AMD. Got it. Okay. So then in terms of like your advice to investors would essentially be like you're kind of rooting for Cirovec to work so that you guys can essentially come in with a kind of more optimized delivery format of IVT versus subretinal? Yeah. I think IBT versus subretinal and the molecules that we express, we think, give us a strong competitive advantage. We've heard from physicians and clinics over and over again that an individual will have a huge competitive advantage over subretinol, but we certainly wish them the best and hope they succeed. Yeah. And then, you know, Chris, I want to come back to you on that point. So I think you guys hosted this Investor Day in New York City a few weeks ago, I think you guys did a nice job of walking through, bringing it to life, of what this will actually look like in a real-world setting and the importance of fitting into the practice flow. Can I ask you to just kind of go through a couple of the highlights of that and how you see your product differentiated in terms of its ability to kind of work into a pretty established kind of chronic VEGF practice? Yeah, absolutely. Most of my comments will be relative to the U.S. model. Of course, of course. But I think some of them are applicable worldwide as well. the average retina clinic or clinic that's administering intravitreal injections is super busy. It's not uncommon today in the U.S. for a retina doc on an injection day to see 50, 60, maybe upwards as high as 80 patients in a day. They're pretty well run. They've kind of perfected that model. But what's really important in that model, and doctors will tell you that, is they don't want a procedure to disrupt that too much. They want it to seamlessly fit into the model, both from an operational standpoint, but also from a reimbursement standpoint. And this is where the fact that, as David mentioned in the slides, that we're at intervitreal therapy is really important. What that means is that the way that physicians in the U.S. today order their anti-VEGF, how they inventory it in terms of temperature control, how they then get reimbursed for it using the very familiar buy-and-bill reimbursement model, all those things we expect to be the same for 40, 150 in a real-world setting as it is today for their anti‑VEGFR usage. So we think that's a huge advantage for us. Economically in the U.S. as well, these busy retina practices, because of the buy and build reimbursement model, they make a margin on these drugs that they acquire and then they inject. And we think the actual economics that would be associated with a lifelong one-time therapy like 4D150 would actually improve the retina economics that they experience today for three simple reasons. One, we don't know pricing at this point, obviously, but it will certainly be, I think, more priced at a higher point than a single anti-VEGF therapy. So you get reimbursement off of that higher price point, but you also get it up front. We also believe today, we know in the real world, that over a five-year period, about 60% of patients that start on BOLA's anti-VEGFotherapy are no longer on therapy out to five years. In fact, about 40% are off therapy within two years. And we think we can capture the value of those patients, again, with a single injection. so that's incrementally better than the current practice paradigm. And the third point is we did surveys, and 40% of retina docs said, again, in the U.S., that they have no capacity or very limited capacity to see additional patients or to administer new therapies. If we can reduce the treatment burden by upwards of 80% for patients over time, that has a connection to, I think, helping improve capacity of a clinic as well. So all these things, I take, make the economic model better, but back to the core point, the fact that we're at intravitreal therapy enables all of that. Got it. Okay. That's super helpful on both kind of your differentiation versus potential subretinal options, also how this will ultimately work in like a commercial real-world setting. On the point on exovec, like I know we saw kind of in the past in the phase two experience, they had some safety. Can we talk about your program and, you know, what you've seen so far on intraocular inflammation, what you're doing in the phase three around prophylactic steroids, and ultimately, like, what gives you confidence in the safety profile? Yeah, we've been thrilled with the safety profiling to date. So, you know, prior to phase three, at that phase three dose, with the topical steroid regimen, which is very easy to give, you know, we only had a couple of patients in the first six months who had some mild cells present, which then went away, and 100% were inflammation-free after six months. So we're thrilled with that. And, you know, we think that it's not an accident. You know, we invented a capsid for very low dose delivery, efficient delivery through the vitreous and into the retina and evolved it to the low inflammation potential. And so we think it's Not Surprising. That's what we're seeing. And so, we certainly hope to see that continue. Got it. Okay. That makes a ton of sense. I want to talk about the kind of what AMD landscape a bit broadly. So in terms of like some of the things that we have recently seen, like Kodiak had some phase 3 data that was kind of rewarded nicely by the market. And then this morning, I mean, I guess those waking up in the U.S. or, you know, we were already kind of midday. We saw J&J buy a company with, you Know, what seems to be essentially like a better Vibesmo potentially. So, you knows, investors and strategists are kind of saying one thing. Gene therapy is chugging along. I think we're kind of in, like, the prime time of in the next 12 months. We'll really learn a lot more. What are you seeing, kind of hearing from the strategic landscape on where gene therapy kind of fits into this space? Yeah, I think they're very, very excited about it, and we see that in our meetings. But maybe, you know, Chris, you might want to expand on that. Yeah, and Chris, do you have a background here as well, right? Yeah, for good. So what do you mean? This is, I guess, my 14th year in retina in different capacities. In large pharma, I launched a drug called Bealeview, for those that track with the space. It was an amazing launch for about four months. And then I launched the drug called Isovav for geographic attributes. Yes, I spent a lot of time in retina. Clearly, there's strategic interest, right? As I mentioned earlier, it's a $16 billion global market, and it's poised to grow for the foreseeable future, driven by a number of factors. One, the fact that, you know, you have an aging patient population. The unmet need, even with existing therapies, is still pretty high when you consider the fact that a lot of patients fall off therapy. The other shocking fact, and it'll connect back to the point around these other bolus therapies, is I mentioned this earlier, amazingly, patients gain vision when they go on a bolus anti-VEGF therapy. Every data set shows that, and its life-changing. But I think equally amazing and unfortunate is that a Lot of those patients, if not the majority, lose that initial vision gain over time. It's actually more pronounced in some European countries largely because of undertreatment. And we think that's very unfortunate because you have efficacious medicines and patients still lose vision. And the primary reason for that is that they're undertreated. Because coming in to get these injections in your eye is a burden on them and their caregivers. So anyway, while bolus therapies, I think, have been phenomenal for the space, I think the innovation there seems very encouraging as to the points you just referenced with Kodiak and Olin as of this morning, they're all still bolus in nature, and none of them can provide continuous disease control. None of them kind of hold that place of a backbone therapy. That's where we think we differentiate. We think that's what the space needs. And beyond what we think, what is more encouraging for us is that you talk to physicians about that concept of a backbone therapy for a continuous disease. They're super excited about it. In fact, the American Society of Retina Specialists, They do an annual survey, and doctors would say the thing that they're most excited about is gene therapy, right, well above anything else in development. And the last point I'll make, and I think it connects back again to why the interest in this space is high, you talk to patients, and we've done a bunch of patient surveys. When you talk, and this is older patient population, granted, and you talk about gene therapy potential for injection-free, always on treatment, my initial thought was I wasn't sure how patients were going to react to that. patient enthusiasm is off the charts for a therapy like this, and we think those factors, I think, one, positions us well for success, but it also goes back to the point that there's a lot of strategic interest in the space, and I think the next 12 months are going to be pretty informative. Got it. Awesome. So we're coming quickly on time. I want to ask one more question, and then maybe will end on some kind of closing remarks. So David, I mean, among investors, there's definitely like a cohort of investors who are quite well informed on what AMD, and I think some people have picked up on this. I think a lot haven't, that within your forefront trials, you guys have done, I think, some very smart things with respect to optimizing, like how you randomize the types of patients that you randomise, how you determine baselines, howyou do rescues. Can you just talk through a few of those things and how they help ensure that you'll have a successful outcome here? Yeah, absolutely. I mean, phase three clinical trial design is a science and an art, and it's important to get it right. Especially in this case. Yeah, and we've got a great team, and then we also work with the world's best investigators out there to pull this together. So I think when we think about a phase three trial, we think about the patient population, the treatment, and the end endpoints pretty easy, BCVA non-inferiority, that's very well set as a primary, and obviously will also show treatment burden reduction. In terms of the patient population, we actually moved into the frontline setting, which is typical for bolus anti-VEGFs. No one thought it was possible for a gene therapy, but I think given our safety profile and the encouraging efficacy, physicians were like, yeah, let's go frontline, which was remarkable to think that someone who's just been diagnosed would flock to a study like that, but they did. The enrollment rate was very, very high, showing the high end needs. So first of all, front lines. So we think cleaner retinas, less atrophy and fibrosis should add to efficacy and safety. We then excluded patients who have very high CST, retinal thickness, to exclude anatomical abnormalities, which lead to poor response. And then we... After the load. Well, this is before the load. And then after the load, we assess for response. Exactly. So that's probably the most important thing we do to enrich is we require a response over the course of four weeks from an Aflibircept dose to make sure we get patients who are highly responsive. So, that's critical. And we think all three of those things give us a patient population who should give us results that are equal to or superior to our phase two results. Then the question of supplemental, what's day one of BCVA, and that's after, for us, after a couple of Aflibircept injections. So we think that's going to narrow the BCVA variability as our baseline, which gives us more statistical power. We then have supplemental injection criteria that we believe will really protect BCVA as a primary endpoint, make sure the study is successful. So 100 or more on CST patients get rescued, 10 or more worsening on vision, they get rescued or the combination of 50 on Cst and 5 on BCVA. And so that's a little bit more stringency than iPoint had and we think we'll really that plus the potency of our agent will really protect BCVA so in my mind those are the things and then we upsize the study you know we went from 400 all the way up to 525, 530 on these studies, which obviously also helps. So we think we're really well positioned to win. Got it. Awesome. And personally, I mean, I'm super excited for this readout next year. I think this will be kind of one of the more exciting ones. And I mean for investors, like you're always trying to find like some sort of disconnect, right? Like that's what creates opportunity. And like Chris, like you mentioned the exceptional physician feedback that you have. And i think like a lot of investors aren't quite there yet, which creates opportunity so maybe David just to close on that point as you're kind of talking to investors who are starting to do work on 2027 like what's your kind of encouragement of like why people should take a look at fdmt for next year well i think everything we just said today it's it's the right science it'sthe right phase two data the right phase redesign the commercialization opportunity is there it's a massive market will be highly disruptive huge strategic interest and i think right now the disconnect in terms of you know our evaluation of where we would otherwise be is because it's gene therapy and not an antibody, right? That's going to change very quickly once we have data. And people are going to say, okay, gene therapy is here to stay, and this is actually a much, much better way to treat this disease. So stay tuned. We're really excited about the readout coming. All right, awesome. Well, that's all we have time for. Thank you so much to David and Chris and the FDMT team. Thank you to everyone for joining. All right. Thank you.
- Company
- 4D MOLECULAR THERAPEUTICS INC
- Keywords
- 4D MOLECULAR THERAPEUTICS INC